Plain-English translation of NCT05626608 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the Boston Cartesia™ directional electrode, a new type of brain stimulation device designed to treat Parkinson's disease. Researchers want to see whether this newer electrode can better control Parkinson's symptoms—like tremor and involuntary movements—compared to conventional brain stimulation electrodes. The treatment works by sending electrical signals to a specific area of the brain involved in movement control.
Many Parkinson's patients benefit from deep brain stimulation surgery, but existing electrodes can cause side effects like speech problems or eye movement difficulties. This new directional electrode is designed to reduce these side effects while improving symptom control, offering patients a better treatment option.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would undergo brain stimulation surgery to have the new Cartesia™ electrode implanted in your brain. The research team would test two different ways of using the electrode—a new directional method and a conventional method—to see which works better for your symptoms. You would need to attend regular follow-up visits over at least 30 months to have your symptoms monitored and your device adjusted as needed.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
France